EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, and Vector Pharma FZCO of Dubai UAE, the leading full-service distributor for rare disease, oncology and highly specialized therapeutics in the Middle East, North Africa and Turkish markets, announced a strategic partnership to expand services across the Middle East and North African markets.
Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck & Co’s COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.
Many countries are expanding Covid-19 vaccine booster programs or shortening the gap between shots as governments scramble to shore up protection against the new Omicron variant which emerged during November in southern Africa and Hong Kong.
The World Health Organization listed AstraZeneca’s Covid-19 vaccine for emergency use, widening access in the developing world, while sources said the EU is in talks with Moderna on buying more vaccines.
Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.
Global coronavirus cases rose by more than 500,000 for the first time, a record one-day increase as countries across the Northern Hemisphere reported daily spikes.
Global coronavirus cases exceeded 10 million on Sunday according to a Reuters tally, marking a major milestone in the spread of the respiratory disease that has so far killed almost half a million people in seven months.
The coronavirus pandemic is accelerating, with Thursday’s 150,000 new cases the highest in a single day and nearly half of those in the Americas, the World Health Organization (WHO) said.
U.S. President Donald Trump will seek $2.5 billion from Congress to fight the coronavirus epidemic, and U.S. and South Korean militaries are considering scaling back joint training as the virus spreads in Europe and the Middle East.
Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.
